Carsgen Therapeutics Holding
CARsgen Therapeutics Holdings Ltd is a Chinese clinical-stage biopharmaceutical enterprise focused on discovering, developing, and manufacturing chimeric antigen receptor (CAR-T) cell therapies for hematological malignancies and solid tumors. The company advances autological CAR-T candidates including zevorcabtagene autoleucel (CT053) targeting BCMA for multiple myeloma, alongside CT041 targeting Claudin18.2 for gastric cancer. Principal revenue is driven through research milestone payments, strategic development collaborations, and capital raises ahead of commercial market authorization. Core end markets serve clinical trial hospital centers, hematology cancer institutes, and prescription patients across China and North America. CARsgen Therapeutics holds an innovative position in the biopharmaceutical sector as a developer of Claudin18.2-targeted cell therapies for solid tumors. The company is incorporated in the Cayman Islands, headquartered in Shanghai, China, and listed on the Stock Exchange of Hong Kong.
2 of the funds FundTelligence covers report a position in Carsgen Therapeutics Holding.
- Sector
- Health Care
- Country
- China
- Funds holding it
- 2
Funds holding Carsgen Therapeutics Holding
- BlackRock iShares MSCI EM IMI Screened UCITS ETF — BlackRock · 0.01 % (full portfolio disclosed, October 2026)
- DNB Global Enhanced Small Cap — DNB · 0.0 % (full portfolio disclosed, September 2026)